Book Value per Share: Virios (VIRI)

Graphic logo of Virios Therapeutics, Inc. (VIRI)

Virios Therapeutics is implementing breakthrough methods to combat viral infections, protecting its developments with strict patents and rigorous FDA control. The book value per share reflects capital accumulation dynamics, where the level of 0.11 represents the current value. The monopoly potential in fibromyalgia therapy is supported by a flexible virtual manufacturing model that relies on the capacities of external contract partners.

Virios (VIRI): Share Book Value from 07/04/2022 to 10/09/2024

Virios Therapeutics Inc. - analytical breakdowns and key metrics (VIRI)

- price and consensus price forecast:
Price Chart Virios|VIRI - Fair Value Consensus
- market capitalization data:
Market Capitalization Virios Therapeutics, Inc.|VIRI - Company Buyout Price
- book capitalization data:
Net Assets per Single Share Virios Therapeutics|VIRI - Net Asset Value|Market Capitalization to Book Value Ratio virios.com|VIRI - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Virios Therapeutics|VIRI - Long-Term Debt to Capital|Short-Term Debt to Equity Virios|VIRI - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Virios Therapeutics, Inc.|VIRI - Company Long-Term Liabilities|Company Short-Term Debts Virios Therapeutics
Fundamental company valuation:virios.com - VIRI
Manufactured products of Virios

For Virios Therapeutics (VIRI), whose stability depends on the import of components from Asia, the book value per common share serves as an indicator of the actual net asset value per business unit. The current value of 0.11 reflects the remaining equity minus liabilities, allowing an investor to assess the company's intrinsic value and the risks of asset undervaluation amid geopolitical instability.

Competitors of Virios Therapeutics (VIRI)

Net Assets per Single Share Gilead Sciences Inc (GILD)|CDTX - Accounting Value of a Share|Novavax, Inc. - Book Value per Share|CVAC (curevac.com) - Net Assets per Share|Net Assets per Single Share Valneva VALN|Share Book Value Vir Biotechnology Inc|SIGA Corp (SIGA) - Book Value per Share|Accounting Value of a Share Emergent Bio (EBS)|Book Value per Share AVIR (Atea Pharmaceuticals)|Invivyd Inc - Book Value per Share|Net Assets per Single Share Enanta Pharmaceuticals, Inc. (ENTA)|INO: Accounting Value of a Share|HLVX (HilleVax Corp) - Net Assets per Single Share|Kalaris Tx (KLRS) - Accounting Value per Share|DYAI (Dyadic International Inc) - Book Value per Share|Book Value per Share NanoViricides Corp (NNVC)|Talphera (TLPH) - Accounting Value per Share|Accounting Value of a Share Cocrystal Pharma Inc COCP|Accounting Value per Share Traws Pharma TRAW|Net Assets per Single Share Dogwood Therapeutics Inc. DWTX|Book Value per Share QLGN (Qualigen Therapeutics)|ALVR: Net Assets per Share|Net Assets per Single Share vbivaccines.com VBIV|Accounting Value of a Share Vaxart